714 related articles for article (PubMed ID: 17021358)
1. An official ATS statement: hepatotoxicity of antituberculosis therapy.
Saukkonen JJ; Cohn DL; Jasmer RM; Schenker S; Jereb JA; Nolan CM; Peloquin CA; Gordin FM; Nunes D; Strader DB; Bernardo J; Venkataramanan R; Sterling TR;
Am J Respir Crit Care Med; 2006 Oct; 174(8):935-52. PubMed ID: 17021358
[TBL] [Abstract][Full Text] [Related]
2. Antituberculous drug-induced liver injury: current perspective.
Devarbhavi H
Trop Gastroenterol; 2011; 32(3):167-74. PubMed ID: 22332331
[TBL] [Abstract][Full Text] [Related]
3. Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis.
Park WB; Kim W; Lee KL; Yim JJ; Kim M; Jung YJ; Kim NJ; Kim DH; Kim YJ; Yoon JH; Oh MD; Lee HS
J Infect; 2010 Oct; 61(4):323-9. PubMed ID: 20670648
[TBL] [Abstract][Full Text] [Related]
4. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
5. Antituberculosis drugs and hepatotoxicity.
Yew WW; Leung CC
Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
[TBL] [Abstract][Full Text] [Related]
6. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
7. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury.
Devarbhavi H; Singh R; Patil M; Sheth K; Adarsh CK; Balaraju G
J Gastroenterol Hepatol; 2013 Jan; 28(1):161-7. PubMed ID: 23020522
[TBL] [Abstract][Full Text] [Related]
8. Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus/AIDS-coinfected patients under tuberculosis treatment.
Ngouleun W; Biapa Nya PC; Pieme AC; Telefo PB
Int J Mycobacteriol; 2016 Dec; 5(4):482-488. PubMed ID: 27931691
[TBL] [Abstract][Full Text] [Related]
9. Occult hepatitis B virus infection: clinical implications in tuberculosis treatment.
Trigo C; do Brasil PE; Costa MJ; de Castro L
J Viral Hepat; 2016 Dec; 23(12):1027-1035. PubMed ID: 27624908
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injury.
Naidoo S; Evans D; Jong E; Mellet K; Berhanu R
S Afr Med J; 2015 Apr; 105(5):393-6. PubMed ID: 26242667
[TBL] [Abstract][Full Text] [Related]
11. Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment.
Chen L; Bao D; Gu L; Gu Y; Zhou L; Gao Z; Huang Y
BMC Infect Dis; 2018 Jul; 18(1):295. PubMed ID: 29970037
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury.
Kim WS; Lee SS; Lee CM; Kim HJ; Ha CY; Kim HJ; Kim TH; Jung WT; Lee OJ; Hong JW; You HS; Cho HC
BMC Infect Dis; 2016 Feb; 16():50. PubMed ID: 26833347
[TBL] [Abstract][Full Text] [Related]
13. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
Gray EL; Goldberg HF
Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
[TBL] [Abstract][Full Text] [Related]
14. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
Tweed CD; Wills GH; Crook AM; Dawson R; Diacon AH; Louw CE; McHugh TD; Mendel C; Meredith S; Mohapi L; Murphy ME; Murray S; Murthy S; Nunn AJ; Phillips PPJ; Singh K; Spigelman M; Gillespie SH
BMC Med; 2018 Mar; 16(1):46. PubMed ID: 29592805
[TBL] [Abstract][Full Text] [Related]
15. The role of hepatitis B infection in anti-tuberculosis drug-induced liver injury: a meta-analysis of cohort studies.
Zheng J; Guo MH; Peng HW; Cai XL; Wu YL; Peng XE
Epidemiol Infect; 2020 Nov; 148():e290. PubMed ID: 33222713
[TBL] [Abstract][Full Text] [Related]
16. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.
Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe
Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.
Singla R; Sharma SK; Mohan A; Makharia G; Sreenivas V; Jha B; Kumar S; Sarda P; Singh S
Indian J Med Res; 2010 Jul; 132():81-6. PubMed ID: 20693595
[TBL] [Abstract][Full Text] [Related]
18. The susceptibility of anti-tuberculosis drug-induced liver injury and chronic hepatitis C infection: A systematic review and meta-analysis.
Chang TE; Huang YS; Chang CH; Perng CL; Huang YH; Hou MC
J Chin Med Assoc; 2018 Feb; 81(2):111-118. PubMed ID: 29198550
[TBL] [Abstract][Full Text] [Related]
19. Chronic hepatitis B infection and risk of antituberculosis drug-induced liver injury: Systematic review and meta-analysis.
Wang NT; Huang YS; Lin MH; Huang B; Perng CL; Lin HC
J Chin Med Assoc; 2016 Jul; 79(7):368-74. PubMed ID: 27032895
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced liver injury in hospitalized HIV patients: high incidence and association with drugs for tuberculosis.
Tomich LG; Núñez M; Mendes-Correa MC
Ann Hepatol; 2015; 14(6):888-94. PubMed ID: 26436361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
